411 related articles for article (PubMed ID: 16709931)
1. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Kantarjian HM; Talpaz M; O'Brien S; Jones D; Giles F; Garcia-Manero G; Faderl S; Ravandi F; Rios MB; Shan J; Cortes J
Blood; 2006 Sep; 108(6):1835-40. PubMed ID: 16709931
[TBL] [Abstract][Full Text] [Related]
2. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Kantarjian H; O'Brien S; Cortes J; Giles F; Shan J; Rios MB; Faderl S; Verstovsek S; Garcia-Manero G; Wierda W; Kornblau S; Ferrajoli A; Keating M; Talpaz M
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):68-75. PubMed ID: 14734453
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
Kantarjian HM; Cortes JE; O'Brien S; Luthra R; Giles F; Verstovsek S; Faderl S; Thomas D; Garcia-Manero G; Rios MB; Shan J; Jones D; Talpaz M
Blood; 2004 Oct; 104(7):1979-88. PubMed ID: 15198956
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M
Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
Kantarjian H; Talpaz M; O'Brien S; Giles F; Faderl S; Verstovsek S; Garcia-Manero G; Shan J; Rios MB; Champlin R; de Lima M; Cortes J
Cancer; 2005 May; 103(10):2099-108. PubMed ID: 15830345
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Cortes JE; Talpaz M; Giles F; O'Brien S; Rios MB; Shan J; Garcia-Manero G; Faderl S; Thomas DA; Wierda W; Ferrajoli A; Jeha S; Kantarjian HM
Blood; 2003 May; 101(10):3794-800. PubMed ID: 12560227
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
[TBL] [Abstract][Full Text] [Related]
10. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Giles F; Rios MB; Shan J; Letvak L; Thomas D; Faderl S; Ferrajoli A; Cortes J
Blood; 2004 Apr; 103(8):2873-8. PubMed ID: 15070658
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on imatinib mesylate in chronic myeloid leukemia.
Curran MP; Croom KF; Goa KL
BioDrugs; 2004; 18(3):207-10. PubMed ID: 15161340
[TBL] [Abstract][Full Text] [Related]
12. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
13. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
14. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
15. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Jabbour E; Kantarjian HM; Abruzzo LV; O'Brien S; Garcia-Manero G; Verstovsek S; Shan J; Rios MB; Cortes J
Blood; 2007 Oct; 110(8):2991-5. PubMed ID: 17625066
[TBL] [Abstract][Full Text] [Related]
16. Imatinib: a review of its use in chronic myeloid leukaemia.
Moen MD; McKeage K; Plosker GL; Siddiqui MA
Drugs; 2007; 67(2):299-320. PubMed ID: 17284091
[TBL] [Abstract][Full Text] [Related]
17. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase.
Palandri F; Castagnetti F; Iacobucci I; Martinelli G; Amabile M; Gugliotta G; Poerio A; Testoni N; Breccia M; Bocchia M; Crugnola M; Rege-Cambrin G; Martino B; Pierri I; Radaelli F; Specchia G; Pane F; Saglio G; Rosti G; Baccarani M
Haematologica; 2010 Aug; 95(8):1415-9. PubMed ID: 20305139
[TBL] [Abstract][Full Text] [Related]
18. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.
Roy L; Guilhot J; Krahnke T; Guerci-Bresler A; Druker BJ; Larson RA; O'Brien S; So C; Massimini G; Guilhot F
Blood; 2006 Sep; 108(5):1478-84. PubMed ID: 16627756
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Cojbasić I; Macukanović-Golubović L
Srp Arh Celok Lek; 2010; 138(5-6):305-8. PubMed ID: 20607973
[TBL] [Abstract][Full Text] [Related]
20. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL
Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]